Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Celltrion: Clinical Trials & FDA Approval Profile

Celltrion (Global / Institutional) sponsors 23 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (2 recruiting now), 16 completed protocols, and 12 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.3%
Median Closed Enrollment vs National (145 pts)473 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Celltrion
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)23
Active Pipeline (Recruiting Now)5 (2)
Completed vs Stopped Early16 / 1 (4.3%)
Median Closed Actual Enrollment473 participants
Physical Hospital Site Disclosure94.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals12 (11 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Celltrion Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI